Standing on shaky ground- US patent-eligibility of isolated DNA and genetic diagnostics after AMP v. USPTO - Part I (Legal context & outcome)
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Standing on shaky ground- US patent-eligibility of isolated DNA and genetic diagnostics after AMP v. USPTO - Part I (Legal context & outcome). / Minssen, Timo; Nilsson, David.
In: Queen Mary Journal of Intellectual Property, Vol. 1, No. 3, 2011, p. 223 - 247.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Standing on shaky ground- US patent-eligibility of isolated DNA and genetic diagnostics after AMP v. USPTO - Part I (Legal context & outcome)
AU - Minssen, Timo
AU - Nilsson, David
N1 - Published in November 2011 (Part I). Part II is expected to be published in Voume 2, Issue 1 in January 2012.
PY - 2011
Y1 - 2011
N2 - This study analyzes the context, outcome and implications of the recent U.S. Federal Circuit decision in AMP v. USPTO, which was announced on July 29, 2011. The decision, which is also referred to as the ACLU/Myriad "gene patenting" case, partially overturned a much debated summary judgment by the District Court for the Southern District of New York, which had held unpatentable claims to isolated DNA per se, as well as claims directed to diagnostic methods relying on the claimed DNA, and processes for cell-based drug screening. Part I first recapitulates the rather complex procedural history of this specific case and explains in more detail how it relates to the recently invigorated U.S. debate on patent eligibility and the U.S. Supreme Court decision in Bilski. Next, the basic outcome of the case will be summarized. The synopsis includes an account of the majority opinion authored by Judge Lourie, as well as a short description of the separate opinions by Judge Moore and Judge Bryson. Part II, which is deemed to be published in Volume 2, Issue 1, will provide a comprehensive analysis discussing the decision's actual potential implications from a broader innovation perspective, as well as the chances for an ultimate Supreme Court review. Based on the analysis, this article finally presents some general conclusions
AB - This study analyzes the context, outcome and implications of the recent U.S. Federal Circuit decision in AMP v. USPTO, which was announced on July 29, 2011. The decision, which is also referred to as the ACLU/Myriad "gene patenting" case, partially overturned a much debated summary judgment by the District Court for the Southern District of New York, which had held unpatentable claims to isolated DNA per se, as well as claims directed to diagnostic methods relying on the claimed DNA, and processes for cell-based drug screening. Part I first recapitulates the rather complex procedural history of this specific case and explains in more detail how it relates to the recently invigorated U.S. debate on patent eligibility and the U.S. Supreme Court decision in Bilski. Next, the basic outcome of the case will be summarized. The synopsis includes an account of the majority opinion authored by Judge Lourie, as well as a short description of the separate opinions by Judge Moore and Judge Bryson. Part II, which is deemed to be published in Volume 2, Issue 1, will provide a comprehensive analysis discussing the decision's actual potential implications from a broader innovation perspective, as well as the chances for an ultimate Supreme Court review. Based on the analysis, this article finally presents some general conclusions
KW - Faculty of Law
KW - Patents, Diagnostics, Myriad
M3 - Journal article
VL - 1
SP - 223
EP - 247
JO - Queen Mary Journal of Intellectual Property
JF - Queen Mary Journal of Intellectual Property
SN - 2045-9807
IS - 3
ER -
ID: 34422736